The objective of this study is to assess the safety and tolerability of KRN23 after a single subcutaneous (SC) administration in subjects with X-linked hypophosphatemic rickets/osteomalacia (XLH) in Japan or Korea.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
15
Single SC administration on day 1: 0.3, 0.6 and 1.0 mg/kg
Unnamed facility
Tokyo, Japan
Unnamed facility
Seoul, South Korea
Number and types of adverse events
The safety of KRN23 assessed by number and types of adverse events, laboratory tests
Time frame: Up to 7 weeks after dosing
Profiles of pharmacokinetics
Time frame: Pre-dose, 24, 48, 96, 168, 336, 504, 672, 840, 1176 hours post-dose
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.